NANTES, FRANCE and BOOXMER, NETHERLANDS--(Marketwire - July 15, 2009) -
VIVALIS AND
INTERVET/SCHERING-PLOUGH ANIMAL HEALTH SIGN A COMMERCIAL LICENSE TO USE THE
EB66® CELL LINE FOR VIRAL VACCINE PRODUCTION AND EVALUATE THE PLATFORM
FOR 12 NEW VACCINES.
VIVALIS (NYSE Euronext: VLS) and INTERVET/SCHERING-PLOUGH ANIMAL HEALTH
today announced the signing of a commercial license, based on the letter of
intent signed in 2008, to use the EB66® cell line, a VIVALIS proprietary
technology, for the production of a veterinary vaccine. Moreover, through
this agreement, INTERVET/SCHERING-PLOUGH ANIMAL HEALTH is also granted
rights to test the EB66® cell line for the production of 12 different
pathogens.
"VIVALIS is pleased to enter into this new agreement with
INTERVET/SCHERING-PLOUGH ANIMAL HEALTH, a worldwide leader in animal health
vaccines. This agreement highlights that the EB66® cell line became a new
industry standard for the production of vaccines." said Franck Grimaud,
VIVALIS CEO.
Terms of the agreement were not disclosed.
About the EB66® cell line.
EB66® cell line, derived from duck embryonic stem cells, presents unique
industrial and regulatory characteristics such as long-term genetic
stability, immortality and cell growth to high cell densities in suspension
in a serum-free medium.
The BMF (Biologics Master File) for the registration of the EB66® cell
line with the FDA (U.S. Food and Drug Administration) was filed June 27,
2008.
EB66® cell line is currently used or tested by 75% of the major players
in vaccines. With 27 licenses already signed, the EB66® cell line is
becoming a new standard cell substrate for biologics production.
*******************
Next financial press release:
22 July, after NYSE Euronext market closing: 2009 first-half sales
About Vivalis
VIVALIS (NYSE Euronext: VLS) is a biopharmaceutical company that provides
innovative cell-based solutions to the pharmaceutical industry for the
manufacture of vaccines and proteins, and develops drugs for the prevention
and treatment of viral diseases. VIVALIS' expertise and intellectual
property are exploited in three main areas:
1. The development and manufacturing of vaccines. VIVALIS offers research
and commercial licenses for its EB66® cell line, derived from duck stem
cells, to pharmaceutical and biotechnology companies for the production of
vaccines. Vivalis receives upfront fees, milestone payments and royalties
on its licensees' net sales.
2. The development of production systems for recombinant proteins and
monoclonal antibodies. VIVALIS licenses its EB66® cell line for the
production of recombinant proteins to biotechnology and pharmaceutical
companies. Vivalis receives upfront fees, milestone payments and royalties
on its licensees' net sales.
3. The construction of a portfolio of proprietary products in the area of
vaccines and anti-viral molecules (hepatitis C).
Based in Nantes (France), VIVALIS was founded in 1999 by the Grimaud group
(1,450 employees), the second largest group worldwide in animal genetic
selection. VIVALIS has established more than 30 partnerships and licenses
with world leaders in this sector, including Sanofi Pasteur,
GlaxoSmithKline, Merck, CSL Kaketsuken, Merial, Intervet Schering Plough,
SAFC Biosciences. VIVALIS is a member of the French ATLANTIC BIOTHERAPIES
bio-cluster.
Learn more about Vivalis at www.vivalis.com
+-------------------------+-+
|VIVALIS | |
+-------------------------+-+
|Listed on Euronext Paris | |
|- Compartment C of NYSE | |
|Euronext | |
+-------------------------+-+
|Reuters: VLS.PA - | |
|Bloomberg: VLS FP | |
+-------------------------+-+
|Included in NYSE | |
|Euronext's Next Biotech | |
|index | |
+-------------------------+-+
+-------------------------+-+
About Intervet/Schering-Plough Animal Health
Intervet/Schering-Plough Animal Health is focusing on the research,
development, manufacturing and marketing of animal health products. The
company offers customers one of the broadest, most innovative animal health
portfolios, spanning products to support performance and to prevent, treat
and control disease in all major farm and companion animal species. For
more information about Intervet/Schering-Plough Animal Health visit the
following website: www.intervet.com
This information is provided by HUGIN
